Results 21 to 30 of about 8,952 (190)

Pemphigoid diseases in infancy and childhood. A review of the literature

open access: yesPrzegląd Dermatologiczny, 2023
Bullous pemphigoid is an autoimmune blistering disease that very rarely affects children. Clinical differences in locations of skin lesions led to the distinction of infantile versus childhood pemphigoid. Mucous membranes can be affected.
Magdalena Jałowska   +2 more
doaj   +1 more source

Paraneoplastic bullous pemphigoid – A sign of clear cell renal carcinoma

open access: yesUrology Case Reports, 2020
Paraneoplastic bullous pemphigoid is a rare paraneoplastic syndrome. Rash is pruritic, with erythematous eruption of large subepidermal bullae over skin and often mucosal surfaces.
Stuart R. Jackson   +5 more
doaj   +1 more source

Bullous pemphigoid

open access: yesIndian Journal of Dermatology, Venereology, and Leprology, 2011
Bullous pemphigoid (BP) is a relatively common autoimmune vesicobullous disease encountered in India. It is a subepidermal bullous disorder most commonly seen in the elderly and manifests as tense blisters on urticarial base, predominantly over flexures, and is associated with pruritus.
Sujay, Khandpur, Parul, Verma
openaire   +2 more sources

Regression of cutaneous squamous cell carcinoma after the development of pembrolizumab‐induced bullous pemphigoid

open access: yesJEADV Clinical Practice, 2023
Bullous pemphigoid is a rare complication of immune checkpoint inhibitor treatment. We report a case of pembrolizumab‐induced bullous pemphigoid in a patient with malignant melanoma and concomitant cutaneous squamous cell carcinoma that regressed.
Shin Iinuma   +2 more
doaj   +1 more source

Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature

open access: yesActa Dermato-Venereologica, 2021
Bullous pemphigoid constitutes a rare dermatological immune-related adverse event of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors.
Aikaterini Tsiogka   +2 more
doaj   +1 more source

Bullous Pemphygoid and Novel Therapeutic Approaches

open access: yesBiomedicines, 2022
Bullous pemphigoid is a subepidermal blistering disease associated with autoantibodies (auto-ab) to BP180 and BP230 which affects elderly patients, predominately.
Giovanni Marco D’Agostino   +10 more
doaj   +1 more source

Correlation between bullous pemphigoid and type 2 inflammation

open access: yesPifu-xingbing zhenliaoxue zazhi, 2022
Bullous pemphigoid (BP) is one of the common autoimmune blister diseases that mainly affects the elderly. Most bullous pemphigoid patients have obvious symptom of pruritus, accompanied by elevated levels of serum total IgE, peripheral blood eosinophils ...
Yao ZHOU   +6 more
doaj   +1 more source

Esophageal Bullous Pemphigoid

open access: yesEuropean Journal of Case Reports in Internal Medicine, 2022
Bullous pemphigoid is a rare autoimmune dermatologic disease that usually occurs in the elderly. Mucous membrane lesions occur in about 10–35% of patients and are almost always limited to the oral mucous membrane. Esophageal involvement is very rare (4% of cases) and usually presents with chest pain, dysphagia, and odynophagia, though patients are ...
Castelo Branco, Catarina   +2 more
openaire   +4 more sources

A Systematic Review of Drug-Induced Pemphigoid

open access: yesActa Dermato-Venereologica, 2020
Bullous pemphigoid is an autoimmune subepithelial disease characterised by pruritus followed by urticarial plaques and finally bullae on the skin and mucosa.
Matthew J. Verheyden   +2 more
doaj   +1 more source

Lower Extremity Salvage in the Setting of Bullous Pemphigoid Exacerbation: A Case Report

open access: yesPlastic and Reconstructive Surgery, Global Open, 2021
Summary:. Bullous pemphigoid is an autoimmune blistering disease where patients suffer from painful bullae, often covering large portions of the skin and requiring management with immune-suppression.
Samara E. Pollock, MD   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy